Waaree Energies share price slips over 6% after Income Tax Department searches — company cooperating Waaree shares slid after IT searches. The company is cooperating and posted robust Q2 results, but investors await more clarity on the probe.

#WaareeEnergies #StockMarketNews #SolarStocks #IncomeTax #WaareeSharePrice #MarketUpdate #Q2Results

Groww Shares Slide 10% in First Post-Listing Decline; Key Dates Nov 21 and Dec 10 in Focus Shares of Billionbrains Garage Ventures Ltd., the parent company of investing platform Groww, witnessed their first major setback on Wednesday, November 19. The Groww share price fell nearly 10%, hitting the lower circuit for the first time since its listing last week. The stock had surged close to 90% above its IPO price of ₹100 by Tuesday’s close.

#Groww #GrowwSharePrice #ShareMarket #StockMarketIndia #GrowwShares #LowerCircuit #NSE #BSE #GrowwIPO #MarketNews #StockMarketToday #InvestingIndia #ShareMarketUpdate #Q2Results #FinanceNews #BusinessNews #EconomyIndia #TradingNews #MarketVolatility

Ashok Leyland Q2 Results: Net Profit Rises 7% YoY To Rs 755.8 Crore; Re 1 Dividend Declared Ashok Leyland Q2 Results: Its revenue from operations in July-September 2025 increases 9.3% to Rs 9,588 crore, compared with Rs 8,769 crore in the year-ago period.

Web Server Hosting Ashok Leyland Q2 Results: Net Profit Rises 7% YoY To Rs 755.8 Crore; Re 1 Dividend Declared Arise Server #AshokLeyland #Q2Results #NetProfit #BusinessNews #DividendDeclared

BEL Q2 Results: Net Profit Jumps 17.8% YoY To Rs 1,287 Crore, Revenue Surges 25.8%

Web Server Hosting BEL Q2 Results: Net Profit Jumps 17.8% YoY To Rs 1,287 Crore, Revenue Surges 25.8% Arise Server #BEL #Q2Results #NetProfit #RevenueGrowth #BusinessNews

#Bullish #CryptoExchange #KriptoBorsa #Q2Results #BlockchainNews #KriptoHaber #CryptoTrading #Fintech #Stablecoin #BullishExchange

Austrian economy grows 0.3% in Q2, but marks ninth straight annual decline Investing.com -- Austria’s economy expanded by 0.3% in the second quarter of 2025 compared to the previous quarter, according to preliminary calculations published Friday by Statistics Austria. The quarterly growth figure exceeded the preliminary estimate of 0.1% released a month ago by the Austrian Institute of Economic Research (WIFO). Despite this quarterly improvement, the Austrian gross domestic product (GDP) contracted by 0.1% on an annual basis, marking the ninth consecutive quarter of year-over-year decline. The GDP components showed mixed performance across the Austrian economy. Private consumption decreased by 0.2% quarter-on-quarter, while public consumption fell by 0.1%. In contrast, gross investment emerged as a bright spot, growing by 0.7% compared to the previous quarter. Exports made only a modest contribution to growth, increasing by 0.1% from the first quarter. Imports declined by 0.6%, representing the first quarterly decrease in four quarters. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Which stocks should you consider in your very next trade? The best opportunities often hide in plain sight—buried among thousands of stocks you'd never have time to research individually. That's why smart investors use our Stock Screener with 50+ predefined screens and 160+ customizable filters to surface hidden gems instantly. For example, the Piotroski's Picks method averages 23% annual returns by focusing on financial strength, and you can get it as a standalone screen. Momentum Masters catches stocks gaining serious traction, while Blue-Chip Bargains finds undervalued giants. With screens for dividends, growth, value, and more, you'll discover opportunities others miss. Our current favorite screen is Under $10/share, which is great for discovering stocks trading under $10 with recent price momentum showing some very impressive returns!

Click Subscribe. #AustrianEconomy #EconomicGrowth #Q2Results #AnnualDecline #InvestmentNews

Amer Sports stock falls despite strong Q2 results and raised guidance NEW YORK -- Amer Sports, Inc. (NYSE:AS) stock fell 5% on Tuesday despite the company reporting better-than-expected second-quarter results and raising its full-year guidance. The sportswear and equipment maker posted earnings per share of $0.06, exceeding analyst estimates of a $0.02 loss, while revenue jumped 23% to $1.24 billion. The company demonstrated strong performance across its portfolio, with Technical Apparel revenue increasing 23% to $509 million and Outdoor Performance segment surging 35% to $414 million, driven by Salomon footwear’s acceleration. Ball (NYSE:BALL) & Racquet Sports segment grew 11% to $314 million. Despite the positive results, investors appeared concerned about slowing growth at the company’s premium Arc’teryx brand and higher selling, general and administrative expenses, which increased 23% YoY to $698 million. Amer Sports raised its full-year 2025 outlook, now projecting revenue growth of 20-21%, up from previous guidance. The company also increased its adjusted operating margin forecast to 11.8-12.2% and expects full-year EPS of $0.77-$0.82, compared to the analyst consensus of $0.78. The company also announced a leadership change, with Wilson CEO Joe Dudy stepping down effective August 31. CFO Andrew Page will serve as interim CEO of Wilson while maintaining his current role. "Overall 2Q was a solid quarter, however, slightly weaker Arc growth/tepid Americas growth and higher 2H SG&A spend could hold back the stock," noted Citi analyst Paul Lejuez. The company’s guidance incorporates the current 30% incremental U.S. tariff on goods from China, though management expects the impact on consolidated results to be negligible this year due to mitigation strategies already underway. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #AmerSports #StockMarket #Q2Results #Investing #Stocks

DocMorris reports weak Q2 with Rx growth below expectations Investing.com -- DocMorris AG on Tuesday reported disappointing second-quarter results, with prescription (Rx) growth falling short of expectations at just 4.6% quarter-over-quarter in local currency, totaling CHF56 million. The Swiss online pharmacy posted external revenues of CHF276 million in Q2 2025, representing a 3% year-over-year increase but a 7% quarter-over-quarter decline. This performance reflects seasonal softness and the impact of German holidays. German prescription sales were the only domestic growth driver, rising 4% quarter-over-quarter and 31% year-over-year to CHF56 million, though this trajectory remains behind expectations and main competitor RDC. Over-the-counter (OTC) and Services declined 10% quarter-over-quarter and 3% year-over-year to CHF203 million, partly due to the discontinuation of the Zur Rose (SIX:DOCM) brand and strong foreign exchange headwinds. One bright spot was TeleClinic, which grew rapidly by over 150% compared to the same period last year. The European segment also showed positive momentum, growing 4% quarter-over-quarter to CHF17 million. Adjusted EBITDA remained largely unchanged at -CHF29 million despite the 4% better top line. Regional adjusted EBITDA in Germany declined 44% year-over-year. Reported EBIT was down 10% half-over-half and 13% year-over-year due to continued marketing investments, particularly burdened by upfront costs for the TV campaign in Q1. Operating cash flow (-CHF56 million) and free cash flow (-CHF144 million) were particularly weak in the first half and need significant improvement to meet management’s target of breaking even within the next 2.5 years. Despite these challenges, DocMorris reiterated its full-year 2025 guidance, including over 10% external sales growth and adjusted EBITDA of -CHF35 million to -CHF40 million, which factors in CHF15 million of incremental Rx marketing spend. Prescription sales are expected to grow at least 40% this year, with capital expenditure remaining at CHF35-40 million. The company continues to expect EBITDA break-even in 2026 and free cash flow break-even during 2027. The EBITDA guidance implies a clear step-up of more than 170 basis points in profitability for the second half of 2025. With the European Court of Justice ruling on prescription bonuses now in place and marketing intensity ramping up, the second half of 2025 should be a constructive period for prescription adoption, potentially offering investors greater visibility and reducing uncertainty over future growth. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year.. In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if DOCM is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.

Click Subscribe #DocMorris #RxGrowth #PharmacyNews #Q2Results #Investing

Russia’s economic growth slows to 1.1% in Q2 amid war pressures Investing.com -- Russia’s economic growth slowed to 1.1% year-on-year in the second quarter of 2025, down from 1.4% in the first quarter, suggesting the economy narrowly avoided a technical recession. The Q2 figure came in slightly above some expectations of 1.0% but below the Bloomberg consensus forecast of 1.5%. This marks a continued cooling of the Russian economy, which is facing mounting pressures from imbalances related to the ongoing war effort. While Rosstat did not release seasonally-adjusted figures, estimates indicate the year-on-year data translates to modest quarterly growth of approximately 0.3%, following an estimated 1.5% quarter-on-quarter contraction in Q1. Industrial production showed relative resilience during the second quarter, growing at 1.8% year-on-year, which likely helped offset weakness across other sectors of the economy. Economic analysts project further slowing of growth in the coming quarters as the Russian economy continues to struggle with structural challenges stemming from the war. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. AI computing powers are changing the stock market. Investing.com's ProPicks AI includes 6 winning stock portfolios chosen by our advanced AI. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. Which stock will be the next to soar?

Click Subscribe. #Russia #EconomicGrowth #Q2Results #WarImpact #Economy

Advance Auto Parts slips as soft full-year guide offsets Q2 beat Investing.com -- Advance Auto Parts (AAP) shares slipped around 1% in premarket trading as the company’s soft full-year profit guide offset the better-than-expected Q2 results. The automotive aftermarket parts provider posted second-quarter earnings per share of $0.69, beating the analyst consensus of $0.53 Revenue was $2 billion, down from $2.2 billion in the year-ago quarter, and compared with expectations of $1.97 billion. Comparable store sales rose 0.1% in the quarter. "The Advance team delivered solid second-quarter results, with both sales and operating margin at the upper end of our expectations," said Shane O’Kelly, president and CEO. "Our comparable sales performance was fueled by growth in the Pro business, and we are encouraged by the early signs of stabilization in our DIY business. For fiscal 2025, the company projects earnings between $1.20 and $2.20 per share, the midpoint of which is below the $1.85 consensus. Revenue is expected to be in the range of $8.52 billion to $8.6 billion, compared to the $8.52 billion consensus estimate. Comparable store sales are expected to grow between 0.5% and 1.5% for the year. With AAP making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed AAP alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including AAP, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is AAP poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #AdvanceAutoParts #AAP #Q2Results #EarningsReport #StockMarket

Polish economy grows 0.8% in Q2, showing resilience amid trade challenges Investing.com -- Poland’s economy expanded by 0.8% quarter-on-quarter in the second quarter of 2025, slightly below consensus expectations of 1.0% but maintaining solid momentum. The growth follows a 0.7% expansion in the first quarter, indicating consistent economic performance. While the latest data release does not include a detailed breakdown, monthly activity indicators reveal strong performance in key sectors. Retail sales showed particularly robust growth of 2.5% quarter-on-quarter in Q2, suggesting consumer-facing sectors continue to provide significant support to the Polish economy. Industrial production also demonstrated resilience with a 1.0% quarterly increase, indicating limited impact from US tariffs so far. The economic performance supports the view that Poland will rank among the best performing economies in the European Union this year, despite ongoing trade challenges. The country’s ability to maintain growth momentum comes amid broader concerns about tariff impacts on European economies. The Q2 figures provide evidence of Poland’s economic strength even as it navigates international trade tensions and adjusts to changing global market conditions. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. AI computing powers are changing the stock market. Investing.com's ProPicks AI includes 6 winning stock portfolios chosen by our advanced AI. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. Which stock will be the next to soar?

Click Subscribe. #PolishEconomy #EconomicGrowth #Resilience #TradeChallenges #Q2Results

Jenoptik reports weak Q2, lowers guidance to bottom of range Investing.com -- Jenoptik AG reported weak second quarter results and now expects its 2025 performance to be at the lower end of its previously announced guidance range. The company posted Q2 sales of €255 million, a 10.5% year-over-year decline and 2% below consensus estimates of €260 million. The drop was primarily driven by weakness in the Semiconductor & Advanced Manufacturing business, which fell 15% in the quarter. While Jenoptik achieved revenue growth in the Americas, sales in Germany, Europe, and Asia/Pacific regions failed to reach last year’s levels. Q2 EBITDA came in at €42.6 million, down 25.2% from the same period last year, with margins declining to 16.7% compared to 20.0% in Q2 2024. Despite the decline, this figure beat consensus expectations of €45.6 million by 7%. Jenoptik now expects its full-year 2025 revenue to fall within the lower half of its previously communicated forecast range of plus or minus 5% relative to 2024’s €1,116 million. Similarly, the EBITDA margin is projected to align with the lower half of the earlier forecast range of 18.0-21.0%, compared to 19.9% in 2024. The company maintains its expectation for a recovery in demand during the second half of the year, particularly in the semiconductor equipment sector. However, this outlook faces increased risk due to existing and potential additional trade barriers. Order intake improved significantly in Q2 to €268.1 million compared to Q1’s €204.6 million, though the first-half total of €472.7 million remained below the prior year’s level of €524.4 million. Jenoptik also announced that the planned sale of Prodomax is no longer feasible within the current strategic timeframe, which extends through the end of 2025. This decision comes amid ongoing challenges in the North American automotive sector, investment restraint, and continued uncertainty surrounding tariffs. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With JENGn making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed JENGn alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including JENGn, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is JENGn poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #Jenoptik #Q2Results #EarningsReport #StockMarket #Investing

Singapore says GDP up 4.4% y/y in Q2, upgrades 2025 forecast SINGAPORE (Reuters) -Singapore’s economy grew by 4.4% in the second quarter of 2025 from a year earlier, government data showed on Tuesday, slightly higher than an advance estimate of 4.3% released last month. On a quarter-on-quarter, seasonally-adjusted basis, gross domestic product rose by 1.4% in the April-June period, in line with the advance estimate and following a 0.5% contraction in the first quarter. The trade ministry raised its GDP growth forecast for 2025 to 1.5% to 2.5% from 0.0% to 2.0%, saying it largely reflected a better-than-expected first half performance. In April, the ministry had cut its forecast from 1.0% to 3.0% after the United States announced its plans for global tariffs. "However, the economic outlook for the rest of the year remains clouded by uncertainty, with the risks tilted to the downside," it said in a statement. In a separate statement, Enterprise Singapore said it was keeping its forecast for non-oil exports at growth of 1% to 3% this year, saying it expected some weakness in the second half after a stronger-than-expected start to 2025. "In general, as frontloading activities taper and reciprocal tariffs resume from 7 August 2025, these could weigh on global economic activity and trade," it said in a statement. Despite having a free-trade agreement and running a trade deficit with the U.S., the wealthy financial hub has still been slapped with a 10% tariff rate by Washington. President Trump has also said he would impose a tariff of about 100% on imports of semiconductors, with an exemption for companies that are manufacturing in the U.S. or have committed to do so, and a tariff on pharmaceutical imports that would rise to 150% within 18 months and eventually to 250%. Figures from a central bank report show pharmaceuticals made up 12.3% of the city-state’s exports to the U.S. in 2024, while semiconductors accounted for 1.6% of shipments and other electronics and semiconductor equipment made up 15.0% of exports to the United States. Imports from other Southeast Asian countries have been slapped with much higher tariffs of between 19% and 40%.

Click Subscribe. #Singapore #GDP #EconomicGrowth #Q2Results #ForecastUpgrade

Ziff Davis reports strong Q2 advertising growth amid AI integration Technology publisher beats revenue expectations with 9.8% growth while deploying artificial intelligence across advertising operations.

Ziff Davis reports strong Q2 advertising growth amid AI integration #ZiffDavis #AdvertisingGrowth #Q2Results #ArtificialIntelligence #TechNews

Ziff Davis reports strong Q2 advertising growth amid AI integration Technology publisher beats revenue expectations with 9.8% growth while deploying artificial intelligence across advertising operations.

Ziff Davis reports strong Q2 advertising growth amid AI integration #ZiffDavis #AdvertisingGrowth #Q2Results #ArtificialIntelligence #TechNews

DraftKings Reports Record Q2 2025 Earnings and Growth DraftKings reports record Q2 2025 revenue of $1.51 billion and explores entry into prediction markets amid regulatory challenges.

DraftKings posts record $300.6M EBITDA in Q2 2025, with revenue up 37%. Taking "measured approach" to prediction markets.

igaming-times.com/draftkings-p...

#DraftKings #Q2Results #SportsBetting #Gaming

Square Stock Pops On Q2 Results As Cash App Banking Gains Traction - Investor's Business Daily Square Stock Pops On Q2 Results As Cash App Banking Gains Traction  Investor's Business Daily

Click Subscribe #SquareStock #CashApp #Banking #Q2Results #Investing

Snap Stock Tumbles. Why Q2 Results Are Leaving It Stuck In The 'Penalty Box.' - Investor's Business Daily Snap Stock Tumbles. Why Q2 Results Are Leaving It Stuck In The 'Penalty Box.'  Investor's Business Daily

Click Subscribe #SnapStock #Q2Results #Investors #StockMarket #FinanceNews

Fresenius raises full-year revenue guidance after strong Q2 results Investing.com -- German healthcare group Fresenius SE (ETR:FREG) on Wednesday raised its full-year revenue guidance following strong second-quarter results driven by growth in its Kabi division and solid performance in its Helios hospital unit. The company now expects organic revenue growth of 5-7% for fiscal year 2025, up from its previous forecast of 4-6%, while maintaining its adjusted EBIT growth target of 3-7% at constant exchange rates. Fresenius reported second-quarter revenue of €5,571 million with organic growth of approximately 5%, slightly below consensus estimates of €5,618 million. Adjusted EBIT remained stable at constant exchange rates, with a margin of 11.7%, exceeding analyst expectations of 11.4%. The Kabi division, which specializes in clinical nutrition, pharmaceuticals and medical technologies, delivered 6% organic revenue growth in the quarter. Growth vectors within Kabi increased by 7%, with particularly strong performance in Biopharma, which grew 33% organically, benefiting from biosimilar launches including Tyenne and Conexxence. Kabi’s EBIT margin expanded to 16.4%, driven by cost savings that offset transaction exchange effects and nutrition headwinds in China. The company maintained Kabi’s full-year organic growth forecast in the mid to high single digits, with an adjusted EBIT margin target of 16-16.5%. The Helios hospital division posted 5% organic revenue growth, with Germany delivering 6% organic growth while Spain grew at 3%, impacted by the Easter holiday falling in the second quarter this year versus the first quarter last year. Despite a 5% decline in EBIT due to the phasing out of energy relief funds in Germany, Helios maintained a 10% EBIT margin, supported by strong profitability in Spain. Fresenius also announced plans to sell shares in Fresenius Medical Care (ETR:FMEG) on a pro rata basis following FME’s share buyback announcement, while maintaining its current stake of approximately 28.6%. The company’s net debt to EBITDA ratio stands at 3.1x, slightly above its target corridor of 2.5x-3.0x, which it attributed to the resumption of dividend payments. Strong free cash flow contributed to 8% growth in core earnings per share, supported by lower interest expenses. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is FREG one of them?

Click Subscribe #Fresenius #EarningsReport #Q2Results #RevenueGuidance #StockMarket

Fresenius raises full-year revenue guidance after strong Q2 results Investing.com -- German healthcare group Fresenius SE (ETR:FREG) on Wednesday raised its full-year revenue guidance following strong second-quarter results driven by growth in its Kabi division and solid performance in its Helios hospital unit. The company now expects organic revenue growth of 5-7% for fiscal year 2025, up from its previous forecast of 4-6%, while maintaining its adjusted EBIT growth target of 3-7% at constant exchange rates. Fresenius reported second-quarter revenue of €5,571 million with organic growth of approximately 5%, slightly below consensus estimates of €5,618 million. Adjusted EBIT remained stable at constant exchange rates, with a margin of 11.7%, exceeding analyst expectations of 11.4%. The Kabi division, which specializes in clinical nutrition, pharmaceuticals and medical technologies, delivered 6% organic revenue growth in the quarter. Growth vectors within Kabi increased by 7%, with particularly strong performance in Biopharma, which grew 33% organically, benefiting from biosimilar launches including Tyenne and Conexxence. Kabi’s EBIT margin expanded to 16.4%, driven by cost savings that offset transaction exchange effects and nutrition headwinds in China. The company maintained Kabi’s full-year organic growth forecast in the mid to high single digits, with an adjusted EBIT margin target of 16-16.5%. The Helios hospital division posted 5% organic revenue growth, with Germany delivering 6% organic growth while Spain grew at 3%, impacted by the Easter holiday falling in the second quarter this year versus the first quarter last year. Despite a 5% decline in EBIT due to the phasing out of energy relief funds in Germany, Helios maintained a 10% EBIT margin, supported by strong profitability in Spain. Fresenius also announced plans to sell shares in Fresenius Medical Care (ETR:FMEG) on a pro rata basis following FME’s share buyback announcement, while maintaining its current stake of approximately 28.6%. The company’s net debt to EBITDA ratio stands at 3.1x, slightly above its target corridor of 2.5x-3.0x, which it attributed to the resumption of dividend payments. Strong free cash flow contributed to 8% growth in core earnings per share, supported by lower interest expenses. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Before you buy stock in FREG, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is FREG one of them?

Click Subscribe #Fresenius #Healthcare #Investing #RevenueGrowth #Q2Results

BPER Banca posts solid Q2 results with improved metrics Investing.com -- BPER Banca delivered strong second-quarter 2025 results, exceeding analyst expectations with pre-provision income 12% above forecasts, driven by stronger net interest income and lower operating expenses. The Italian bank reported net interest income 2% above consensus expectations, supported by a 3% quarter-over-quarter increase in loan volumes that helped offset interest rate impacts. Commission income was in line with expectations, showing a 1.2% year-over-year improvement led by market fees and bancassurance fees, which grew 4% and 8% respectively, while commercial banking fees declined 1.9%. Overall revenues came in 4% better than expected, while operating expenses were also 4% lower than anticipated. Human resources costs and headcount decreased by 9% and 6% year-over-year, respectively. Net income beat expectations by 19%, further supported by lower-than-expected loan loss provisions. Asset quality showed improvement with loan loss provisions 18% better than expected at approximately €70 million, representing a cost of risk of 32 basis points in the quarter, up slightly from 30 basis points in the first quarter. The non-performing loan ratio decreased by 10 basis points quarter-over-quarter, while coverage increased to 55.6% from 54.2% in the previous quarter. BPER’s capital position strengthened significantly, with the CET1 ratio reaching 16.2%, up 40 basis points quarter-over-quarter and above the consensus expectation of 15.9%. This improvement was attributed entirely to organic capital generation, net of dividends. The bank updated its 2025 standalone guidance, projecting revenues of €5.5 billion, up from the previous €5.4 billion forecast. Net interest income is expected to decline by mid-single digits, while commission income is projected to increase by mid-single digits. The cost-to-income guidance suggests operating expenses will be 1% below consensus expectations, and the cost of risk is guided at less than 40 basis points. Banco Popolare (BIT:BAMI) di Sondrio (BIT:BPSO), which is being integrated into BPER Banca, also reported strong quarterly results, with net interest income and commissions exceeding forecasts. Management comments regarding the integration process were described as conciliatory, suggesting a potentially smooth merger process. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #BPERBanca #Q2Results #FinancialMetrics #BankingNews #Investing

Tel Aviv Stock Exchange reports strong Q2 with record margins Investing.com -- The Tel Aviv Stock Exchange (TASE) reported a strong second quarter for 2025 on Wednesday, with adjusted EBITDA of ILS 72 million, representing a 56% increase year-over-year and resulting in a record 52.6% adjusted margin. Revenue grew 29% year-over-year to ILS 136 million, exceeding estimates by ILS 3 million. This growth was primarily driven by the clearinghouse segment, where balances are 21% higher compared to when guidance for price increases was initially provided in July 2024. Expenses came in ILS 8 million below estimates, partly due to a lower compensation ratio of 29% versus the estimated 35%. Management indicated that the second quarter expense trajectory represents a reasonable run rate for the remainder of the year. Non-transactional revenues continued to perform well at ILS 87 million, up 31% year-over-year, marking the eighth consecutive quarter of meeting or exceeding the 10-12% five-year CAGR target. Clearinghouse revenues increased 63% year-over-year, with 38% generated from higher activity volumes and services offered. Listing fees rose 16% year-over-year, with 7% attributed to an increase in companies paying annual levies and linkage of those levies to the Consumer Price Index. Data distribution revenues grew 19% year-over-year, with a 9% increase from TASE index authorizations. The exchange’s adjusted EBITDA margins of 52.6% were up 545 basis points from the first quarter. Estimates now project margins of 50.1% for fiscal year 2025, representing a 756 basis point increase year-over-year. In June, TASE’s Board authorized an examination of strategic measures for its index business, including potential partial or full sale, or partnership with a leading international index operator or financial institution. The exchange cited a desire to access a global distribution platform to address increasing international demand for its indices. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #TelAvivStockExchange #Q2Results #RecordMargins #StockMarket #Investing

Astera Labs Stock Surges As Chipmaker Tops Q2 Targets - Investor's Business Daily Astera Labs Stock Surges As Chipmaker Tops Q2 Targets  Investor's Business Daily

Click Subscribe #AsteraLabs #StockMarket #Investing #Q2Results #TechStocks

Adidas’ winning streak faces test as Q2 stirs doubts Investing.com -- Adidas’ bump strong run may be hitting a speed, as softer-than-expected second-quarter results raises questions over the durability of its turnaround. But UBS argues it’s too early to call time on the outperformance. The sportswear giant posted a weaker Q2 top line, dented by sluggish direct-to-consumer sales, a slowdown in footwear, and ongoing challenges in Europe. That raised investor concerns that Adidas’ momentum buoyed in recent quarters by the popularity of its Terrace line and a refreshed brand image, may be running out of steam. UBS cautions against reading too much into a single quarter. The bank notes that while growth from the Terrace franchise has moderated, newer franchises are starting to pick up the slack. Given that it can take up to nine months for new product lines to gain traction, more meaningful contributions are expected in the second half. In Europe, where the quarter’s softness was most pronounced, channel checks still show retailer optimism. And management said sales in the region picked up in July, offering an early sign that the dip may be short-lived. While the U.S. remains a drag, Adidas (OTC:ADDYY) reiterated confidence in double-digit growth for all other markets, which account for about 80% of sales. FX hedging benefits are also expected to shield earnings into 2026. Still, UBS concedes that a more decisive verdict on momentum will have to wait for Q3. Investors will be watching closely to see if new franchises can carry the weight as Terrace cools. At around 24 times 2025 earnings, Adidas trades below the growth implied by its long-term outlook, UBS said, keeping a Buy rating with a price target of €274. But with sentiment on a knife’s edge, another stumble could alter the narrative fast. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if ADSGN is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #Adidas #Q2Results #Investing #Sportswear #Footwear

Amazon tops Q2 estimates with $167.7B in revenue, $19.2B in profits; AWS up 17% to $30.9B An Amazon delivery van parked in front of the company’s headquarters campus and The Spheres in Seattle. (GeekWire Photo / Kurt Schlosser) Amazon beat estimates for its second quarter earnings with $167.7...

Amazon tops Q2 estimates with $167.7B in revenue, $19.2B in profits; AWS up 17% to $30.9B #Technology #Business #IndustryGiants #Amazon #Q2Results #TechEarnings